GlassScriptPhysician profile
Susie Suh
NPI 1467459602
$10,930.52
in general payments reported to CMS, 2019-2025
49 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $769 · 2021: $1,286 · 2022: $1,476 · 2023: $1,573 · 2024: $1,869 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,333 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,333.49 |
| Education | $191.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,289.08 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $2,141.84 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,319.25 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $964.71 | 2019-2025 | |
| Pfizer INC. | $690.54 | 2019-2024 | |
| Glaxosmithkline, LLC. | $588.62 | 2019-2025 | Benlysta |
| Ucb, INC. | $421.69 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $255.64 | 2020-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $233.16 | 2019-2025 | Orencia |
| Mallinckrodt Enterprises LLC | $202.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.79 | 2019-2023 | Ofev |
| Alexion Pharmaceuticals, INC. | $122.56 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $103.29 | 2023-2025 | Lupkynis |
| Octapharma USA, INC. | $92.94 | 2024-2025 | Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $84.97 | 2020-2025 | Actemra, Gazyva |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susie Suh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.